The Experts below are selected from a list of 7071 Experts worldwide ranked by ideXlab platform
Anthony T R Axon - One of the best experts on this subject based on the ideXlab platform.
-
helicobacter pylori eradication does not exacerbate Reflux symptoms in gastroesophageal Reflux disease
Gastroenterology, 2001Co-Authors: Paul Moayyedi, Chandu Bardhan, Lynne Young, M F Dixon, Lorna Brown, Anthony T R AxonAbstract:Abstract Background & Aims: Observational studies have suggested that Helicobacter pylori may protect against Gastrointestinal Reflux disease (GERD), but these results could be due to bias or confounding factors. We addressed this in a prospective, double blind, randomized, controlled trial. Methods: H. pylori –positive patients with at least a 1-year history of heartburn with a normal endoscopy or grade A esophagitis were recruited. Patients were randomized to 20 mg omeprazole, 250 mg clarithromycin, and 500 mg tinidazole twice a day for 1 week or 20 mg omeprazole twice a day and identical placebos. A second concurrently recruited control group of H. pylori –negative patients were given open label 20 mg omeprazole twice a day for 1 week. All patients received 20 mg omeprazole twice a day for the following 3 weeks and 20 mg omeprazole once daily for a further 4 weeks. Omeprazole was discontinued at 8 weeks and patients were followed up for a further 10 months. A relapse was defined as moderate or severe Reflux symptoms. H. pylori eradication was determined by 13 C-urea breath test. Results: The H. pylori –positive cases were randomized to antibiotics (n = 93) or placebo (n = 97). Relapse of GERD occurred in 83% of each of the antibiotic, placebo, and H. pylori –negative groups during the 12-month study period. Life tables revealed no statistical difference between the 2 H. pylori –positive groups (log rank test, P = 0.84) or between the 3 groups (log rank test, P = 0.94) in the time to first relapse. Two patients in each group developed grade B esophagitis at 12 months. Conclusions: H. pylori eradication therapy does not seem to influence relapse rates in GERD patients. GASTROENTEROLOGY 2001;121:1120-1126
Paul Moayyedi - One of the best experts on this subject based on the ideXlab platform.
-
helicobacter pylori eradication does not exacerbate Reflux symptoms in gastroesophageal Reflux disease
Gastroenterology, 2001Co-Authors: Paul Moayyedi, Chandu Bardhan, Lynne Young, M F Dixon, Lorna Brown, Anthony T R AxonAbstract:Abstract Background & Aims: Observational studies have suggested that Helicobacter pylori may protect against Gastrointestinal Reflux disease (GERD), but these results could be due to bias or confounding factors. We addressed this in a prospective, double blind, randomized, controlled trial. Methods: H. pylori –positive patients with at least a 1-year history of heartburn with a normal endoscopy or grade A esophagitis were recruited. Patients were randomized to 20 mg omeprazole, 250 mg clarithromycin, and 500 mg tinidazole twice a day for 1 week or 20 mg omeprazole twice a day and identical placebos. A second concurrently recruited control group of H. pylori –negative patients were given open label 20 mg omeprazole twice a day for 1 week. All patients received 20 mg omeprazole twice a day for the following 3 weeks and 20 mg omeprazole once daily for a further 4 weeks. Omeprazole was discontinued at 8 weeks and patients were followed up for a further 10 months. A relapse was defined as moderate or severe Reflux symptoms. H. pylori eradication was determined by 13 C-urea breath test. Results: The H. pylori –positive cases were randomized to antibiotics (n = 93) or placebo (n = 97). Relapse of GERD occurred in 83% of each of the antibiotic, placebo, and H. pylori –negative groups during the 12-month study period. Life tables revealed no statistical difference between the 2 H. pylori –positive groups (log rank test, P = 0.84) or between the 3 groups (log rank test, P = 0.94) in the time to first relapse. Two patients in each group developed grade B esophagitis at 12 months. Conclusions: H. pylori eradication therapy does not seem to influence relapse rates in GERD patients. GASTROENTEROLOGY 2001;121:1120-1126
Alison Buchan - One of the best experts on this subject based on the ideXlab platform.
-
Two decades of Helicobacter pylori: A review of the Fourth Western Pacific Helicobacter Congress Two decades of Helicobacter pylori: A review of the Fourth Western Pacific
2020Co-Authors: Md Carlo A Fallone, Md Naoki Chiba, Alison Buchan, Diane Taylor, C A Fallone, N ChibaAbstract:, Helicobacter enthusiasts gathered in Perth, Australia for the Fourth Western Pacific Helicobacter Congress to celebrate the 20th anniversary of the modern discovery of this organism by Barry Marshall and Robin Warren. The meeting included state-of-the-art lectures highlighting the breakthroughs that have occurred since the discovery of this bacterium. As well, advances from the forefront of current Helicobacter pylori research were presented, particularly in the realm of genomics and molecular biology. A symposium about vaccines and trends for future H pylori research completed this congress. The purpose of the present review is to summarize the highlights from this conference, emphasizing new advances. Key Words: Fourth Western Pacific Helicobacter Congress; Helicobacter pylori Helicobacter pylori deux décennies plus tard : synthèse du 4e congrès du Pacifique-Ouest sur Helicobacter RÉSUMÉ : Du 3 au 6 mars 2002, des passionnés d'Helicobacter se sont réunis à Perth, en Australie, en vue du 4e congrès du Pacifique-Ouest sur Helicobacter pour souligner le 20e anniversaire de la découverte du microorganisme par Barry Marshall et Robin Warren. Des conférences à la fine pointe de l'actualité ont fait état des percées effectuées dans le domaine depuis la découverte de la bactérie. On y a présenté également les progrès réalisés à l'avant-garde de la recherche sur Helicobacter pylori, notamment en génomique et en biologie moléculaire. Enfin, un colloque sur la mise au point de vaccins contre la bactérie et les tendances de la recherche future sur le micro-organisme a complété le tout. Le présent article vise à présenter une synthèse des éléments saillants du congrès et à mettre en évidence les progrès réalisés dans le domaine. ANIMAL MODELS Several animal models continue to be developed for the study of Helicobacter pylori-associated diseases. Bjorkhölm (USA) described a novel approach to identifying virulenceassociated genes using the germ-free transgenic mouse and microarray technology. The Mongolian Gerbil model was used by Takshi (Japan) to determine that the vacA s2/m2 genotype is a very important virulence factor in the development of a gastric mucosal lesion. Using a mouse model, Rourke (USA) determined that the progression of mucosaassociated lymphoid tissue lymphoma depends on both bacterial virulence factors and how long the infection had been present. Interestingly, other Helicobacter species were found to colonize mouse models. Wadström (Sweden) found that 75% of eight well-known mouse strains were positive for Helicobacter typhlonicus, Helicobacter rodentium, Helicobacter mesocricetorum and H pylori using polymerase chain reaction (PCR)-denaturing gradient gel electrophoresis and DNA sequencing. GENOMICS AND MOLECULAR STUDIES Falkow (USA) presented an excellent overview of customdesigned gene chips to quantify changes in H pylori gene expression. Alterations in gene transcripts between different strains of the bacterium and in response to coculture with a human gastric cell line (AGS) were outlined. Custom-designed mouse and human gene chips (Stanford Genome Centre, USA) track how mammalian gene expression patterns are affected. The mouse model used BALB/C mice infected with the Sydney strain and the human model used AGS cells infected with a virulent strain of H pylori. The data from the human gene chip experiments identified the small GTPase, cdc42, as a major target of H pylori. Falkow then discussed how H pylori affected cell to cell adhesion molecules. A substrain of H pylori capable of attaching to the polarized epithelial cell line, MDCK, was isolated. The attachment sites of these bacteria correlated with the distribution of the tight junction protein, ZO-1. In the same session, Trust (USA) discussed how designer drugs are generated using genomes. The genomes of 61 bacteria are available, and these data can be mined to identify bacteria-specific genes. A subset of essential genes can be determined, and targets for those genes developed. Screening of the H pylori genome unfortunately has not yet identified any obvious drug targets. In a free paper session, the use of new genetic technologies was discussed. S Hjalmarsson (Sweden) dealt with pyro sequencing that gives fast, accurate sequence data on 20-to 25-base pair sections of genes. Further information on the technology can be found at www.pyrosequencing.com. Wadstrom (Sweden) discussed the use of protein chip technology to monitor changes in protein profiles. Blomstergren (Sweden) presented ongoing studies of the total genome analysis of three H pylori strains. His data so far indicate that the cagA gene is highly variable and that changes in the mRNA are translated into changes to the final protein structure. Wu (Taiwan) examined the effect of deleting the flgK gene encoding a flagellar protein homologous to the Escherichia coli hook-associated protein. Deletion had no effect on either adhesion or urease production. The bacteria colonized mice but at a lower density than wild-type bacteria. Buchan (Canada) discussed the use of gene arrays to dissect the differences between primary gastric epithelial cells and commonly used human gastric cell lines infected with H pylori on human gene expression. None of the three human gastric cell lines examined (AGS, NCI-N87 and MKN45) were found to be good models of the normal cells. Infection with H pylori modulated the gene expression and cellular location of proteins involved in cell to cell adhesion and intracellular vesicular trafficking pathways. In a related session, Blaser (USA) dealt with the use of genetic screens (guanine to cytosine ratio, trinucleotide difference index) to identify variable regions in the H pylori genome. These techniques confirmed the existence of multiple regions of genetic variation that show geographical strain differentiation. In individuals infected with H pylori, the bacterium mutates over time. Coevolution of the babA and babB genes was documented in a study of infected individuals in Holland over a seven-year period. The considerable genomic diversity among strains of H pylori was discussed by Taylor (Canada). This diversity has been demonstrated by various molecular typing techniques, direct sequencing and, recently, microarray analysis. Macrodiversity (diversity in gene order) probably occurs by inversion and/or transposition within plasticity zones of low guanine and cytosine content (35%) relative to the rest of the genome (39%). It could account for loss of the cagA pathogenicity island (PAI), resulting in the selection of a less virulent strain. Microdiversity in H pylori is highlighted by the considerable nucleotide divergence due to synonymous substitutions (15% to 21% for H pylori genes compared with 1% to 2% for genes from Salmonella typhimurium strains). In addition, at least 27 genes contain simple nucleotide repeats, including outer membrane proteins, lipoprotein synthesis enzymes and DNA restriction/modification systems, where frameshift mutations are easily generated by replication slippage. H pylori also lacks a methyldirected mismatch DNA repair system, which could increase the frequency of mutation. Such genetic changes control membrane lipid composition and Lewis antigen synthesis genes, the expression of which is known to vary during the course of infection and likely optimize the survival of H pylori in the stomach. HOST BACTERIAL INTERACTIONS Apart from changing itself, H pylori may alter and regulate its environment. Mobley (USA) discussed how this bacterium induces both subtle and dramatic changes in its environment, allowing the organism to persist, in most cases, for decades. These changes include the modulation of the acquired as well as innate immune responses, including alterations in cytokine levels. Cytoskeletal rearrangements in the epithelium are induced by injecting cagA into the host cell via a type IV secretion system synthesized by the bacterium. The pH is modulated by the combination of bacterial urease activity and vacA-mediated urea permeation through the epithelium. Finally, gene expression patterns of nonparietal cells are altered by the presence of the bacterium. The response to colonization by H pylori is usually compatible with a lengthy host-parasite relationship; however, overt damage can result from this interaction. The mechanisms for a number of these host-parasite interactions are now better understood and offer targets for both therapeutic intervention and prevention by vaccination. A free paper session was held on the host immune response. Mitchell (Australia) demonstrated that the cytokine response (interferon gamma in particular) to H pylori in subjects from developed and developing countries may differ. Thus, geography may add to the diversity encountered in all aspects of the host-bacterial interaction. Two interesting talks on the adhesion of H pylori to the host cells via toll-like receptors (TLR) presented contradictory results. Su (Canada) demonstrated that TLR4 might act as a receptor for H pylori. TLR4 RNA is expressed and upregulated by gastric epithelial cells in response to H pylori infection. Protein expression of TLR4 is also increased in this setting. In contrast, Bäckhed (Sweden), who compared TLR mRNA expression from different cell lines, was unable to demonstrate any TLR4 expression in primary gastric epithelial cells and concluded that TLRs are not involved in gastric mucosal recognition of H pylori. H PYLORI AND PEDIATRICS Megraud (France) presented results of a multicentre European Study of over 500 children aged two to 17 years undergoing endoscopy. He confirmed the appropriateness of the 13 carbon urea breath test as a diagnostic test in children (sensitivity 96%, specificity 95%). Serology was not as good, and urine antibody detection was poor. Stool antigen testing results, shown to be excellent in adults (Sheu, Taiwan), were pending in this European pediatric study. Several studies from Aboriginal communities (known to have a high prevalence of H pylori) were also presented, including one from a Northern Manitoba Community (Song, USA), which demonstrated the presence of H pylori via PCR from saliva and nipple samples, supporting the theory of oral-oral transmission. There were few treatment studies in the pediatric population, but Casswall (Sweden) presented results of a large study of 131 patients aged 10 to 21 years using a single daily dose regimen of lansoprazole, azithromycin and tinidazole for six days, achieving 93% compliance. The intention to treat eradication rate, however, was disappointing (63%). H PYLORI AND GASTRIC CANCER Several advances have occurred in the realm of gastric cancer research as it relates to H pylori in recent years. Given the high rate of this disease in Asia and Europe, there are many scientific contributions from these continents. Although a specific symposium was dedicated to gastric cancer in Asia, the theme of gastric cancer kept reappearing throughout much of the meeting. One of the most important recent developments has been the results of a study by Uemura et al In a free paper session, Van Doorn (the Netherlands) identified that, in H pylori-infected Portuguese patients, both vacA and cagA genotypes were associated with an increased risk of gastric carcinoma (odds ratio [OR] 6.7 to 17) and that patients with interleukin (IL)-1 polymorphisms such as IL-1β-511 T carriers and IL-1RN*2 also had an increased risk (smaller OR of 3.3). However, what was particularly striking was that those with both virulent H pylori genotypes in association with human IL-1 polymorphisms had a dramatically increased risk of gastric cancer, suggesting a synergistic interaction between bacterial virulence and host genetic susceptibility (OR as high as 108, 95% CI 10 to 1148 if vacA s1 and IL-1 polymorphism existed). This may partly explain why only some patients develop gastric cancer. There was interest in elucidating the role of cagA+ strains as a marker of increased gastric cancer risk. PAI leads to nuclear factor kappaB and IL-8 secretion, which may play a central role in host response to H pylori infection. CagA is one of the markers of the PAI. Wu (United Kingdom) reported that patients who were seropositive for cagA had a significantly increased risk of distal gastric cancer (OR 2.1, 95% CI 1.1 to 9.3) but no influence on junctional (gastric cardia and esophageal adenocarcinoma) cancer. Previous studies have suggested that patients infected with a cagA-positive strain may be protected against junctional cancers. At this meeting, a recurring warning was that the traditional cagA ELISA serological tests may not be sufficiently sensitive or specific enough and that cagA determination through PCR or immunoblotting was preferred (Shimoyama, Japan; Engstrand, Sweden). Engstrand presented data on 298 Swedish patients with gastric carcinoma and found that 76% were positive for H pylori by ELISA, whereas 88% of those who were negative on ELISA were positive for cagA by immunoblot. This indicates that, unless researchers also look for other markers of H pylori, the gastric cancer risk associated with H pylori could be underestimated. H PYLORI AND ASSOCIATION WITH OTHER CLINICAL DISEASES H pylori is associated with peptic ulcer disease, mucosa-associated lymphoid tissue lymphoma and gastric cancer. Controversial associations include functional dyspepsia, gastroesophageal Reflux disease (GERD) and nonsteroidal anti-inflammatory drug (NSAID)-induced ulcer disease. The role of H pylori in predicting endoscopic findings in patients with uninvestigated dyspepsia from the Canadian Adult Dyspepsia Empiric Therapy -Prompt Endoscopy (CADET-PE) study was presented by Chiba (Canada). In the 1013 patients with available H pylori status, H pylori prevalence was 30% and increased with age. Overall, clinically significant findings were observed in 58% of all patients. Gastric and duodenal ulcers were rare (3% or less for each), but both were more common if H pylori was present (5.6% versus 2.0% and 6.6% versus 1.3%, respectively; each P<0.002). Erosive esophagitis was the most common overall finding. The prevalence of esophagitis was less common in H pylori-positive (36%) than in H pylori-negative (46%) patients (P<0.002). The results of this study suggest that, while endoscopic findings are common, the vast majority would be appropriately treated with empirical acidsuppressive therapy and prompt endoscopy would not necessarily alter initial management. While it is well accepted that H pylori and NSAIDs are the most important causes of duodenal ulcer disease, it is also recognized that there is an increasing population that appears to be negative for H pylori through traditional testing of gastric biopsies. An interesting study demonstrated that H pylori was present in the duodenum of 6.8% of patients who did not have H pylori in their gastric specimens. This report suggests that additional duodenal biopsies may help decrease the prevalence of apparently H pylori-negative ulcer subjects (Kullavanijaya, Thailand). Hawkey et al The effect of H pylori on GERD is still controversial, with some studies suggesting an increased incidence of GERD after H pylori eradication (6,7) and more recent publications (8,9) suggesting that eradication does not worsen GERD. Fallone (Canada) presented the results of an interim analysis demonstrating that GERD patients who were negative for H pylori had more severe GERD, as determined by the Spechler Gastrointestinal Reflux Disease Activity Index, and used proton pump inhibitors more often than infected patients. Other validated GERD severity scores, including questionnaires and 24 h pHmetry, demonstrated similar trends. These results suggest that H pylori infection results in less severe GERD and is in keeping with the CADET-PE data showing that H pyloripositive patients had a lower prevalence of endoscopic esophagitis than uninfected patients. TREATMENT AND ANTIBIOTIC RESISTANCE Koga (Japan), presented a novel finding using probiotics to eradicate H pylori. He found that Lactobacillus gasseri OLL2716 (LG21) eradicated H pylori in mice. In humans, it was shown to decrease urea breath test 13 carbon levels at 24 weeks. In an in vitro study, Vilaichone (Thailand) found that Lactobacillus acidophilus had an inhibitory effect on H pylori in 87% of patients tested. These agents certainly require further study, but it is very exciting to see an agent as innocuous as yogourt work in the treatment of H pylori infection
Lynne Young - One of the best experts on this subject based on the ideXlab platform.
-
helicobacter pylori eradication does not exacerbate Reflux symptoms in gastroesophageal Reflux disease
Gastroenterology, 2001Co-Authors: Paul Moayyedi, Chandu Bardhan, Lynne Young, M F Dixon, Lorna Brown, Anthony T R AxonAbstract:Abstract Background & Aims: Observational studies have suggested that Helicobacter pylori may protect against Gastrointestinal Reflux disease (GERD), but these results could be due to bias or confounding factors. We addressed this in a prospective, double blind, randomized, controlled trial. Methods: H. pylori –positive patients with at least a 1-year history of heartburn with a normal endoscopy or grade A esophagitis were recruited. Patients were randomized to 20 mg omeprazole, 250 mg clarithromycin, and 500 mg tinidazole twice a day for 1 week or 20 mg omeprazole twice a day and identical placebos. A second concurrently recruited control group of H. pylori –negative patients were given open label 20 mg omeprazole twice a day for 1 week. All patients received 20 mg omeprazole twice a day for the following 3 weeks and 20 mg omeprazole once daily for a further 4 weeks. Omeprazole was discontinued at 8 weeks and patients were followed up for a further 10 months. A relapse was defined as moderate or severe Reflux symptoms. H. pylori eradication was determined by 13 C-urea breath test. Results: The H. pylori –positive cases were randomized to antibiotics (n = 93) or placebo (n = 97). Relapse of GERD occurred in 83% of each of the antibiotic, placebo, and H. pylori –negative groups during the 12-month study period. Life tables revealed no statistical difference between the 2 H. pylori –positive groups (log rank test, P = 0.84) or between the 3 groups (log rank test, P = 0.94) in the time to first relapse. Two patients in each group developed grade B esophagitis at 12 months. Conclusions: H. pylori eradication therapy does not seem to influence relapse rates in GERD patients. GASTROENTEROLOGY 2001;121:1120-1126
Lorna Brown - One of the best experts on this subject based on the ideXlab platform.
-
helicobacter pylori eradication does not exacerbate Reflux symptoms in gastroesophageal Reflux disease
Gastroenterology, 2001Co-Authors: Paul Moayyedi, Chandu Bardhan, Lynne Young, M F Dixon, Lorna Brown, Anthony T R AxonAbstract:Abstract Background & Aims: Observational studies have suggested that Helicobacter pylori may protect against Gastrointestinal Reflux disease (GERD), but these results could be due to bias or confounding factors. We addressed this in a prospective, double blind, randomized, controlled trial. Methods: H. pylori –positive patients with at least a 1-year history of heartburn with a normal endoscopy or grade A esophagitis were recruited. Patients were randomized to 20 mg omeprazole, 250 mg clarithromycin, and 500 mg tinidazole twice a day for 1 week or 20 mg omeprazole twice a day and identical placebos. A second concurrently recruited control group of H. pylori –negative patients were given open label 20 mg omeprazole twice a day for 1 week. All patients received 20 mg omeprazole twice a day for the following 3 weeks and 20 mg omeprazole once daily for a further 4 weeks. Omeprazole was discontinued at 8 weeks and patients were followed up for a further 10 months. A relapse was defined as moderate or severe Reflux symptoms. H. pylori eradication was determined by 13 C-urea breath test. Results: The H. pylori –positive cases were randomized to antibiotics (n = 93) or placebo (n = 97). Relapse of GERD occurred in 83% of each of the antibiotic, placebo, and H. pylori –negative groups during the 12-month study period. Life tables revealed no statistical difference between the 2 H. pylori –positive groups (log rank test, P = 0.84) or between the 3 groups (log rank test, P = 0.94) in the time to first relapse. Two patients in each group developed grade B esophagitis at 12 months. Conclusions: H. pylori eradication therapy does not seem to influence relapse rates in GERD patients. GASTROENTEROLOGY 2001;121:1120-1126
